Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
PolyPid ( (PYPD) ) just unveiled an update.
PolyPid Ltd. has announced a research and development collaboration with ImmunoGenesis, Inc. to enhance cancer immunotherapy treatments. This partnership will combine PolyPid’s PLEX technology, facilitating controlled intratumoral drug delivery, with ImmunoGenesis’ STING agonist drug candidate to address the challenge of rapid clearance and improve anti-tumor effectiveness, potentially leading to innovative advancements in immuno-oncology.
More about PolyPid
PolyPid Ltd. is a late-stage biopharma company focused on improving surgical outcomes through its proprietary PLEX technology, which allows for locally administered, controlled, prolonged-release therapeutics. Their lead product candidate, D-PLEX100, is in Phase 3 clinical trials for preventing abdominal colorectal surgical site infections, and they are also in preclinical stages for OncoPLEX, aimed at treating solid tumors such as glioblastoma.
YTD Price Performance: -24.47%
Average Trading Volume: 11,013
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $19.53M
For a thorough assessment of PYPD stock, go to TipRanks’ Stock Analysis page.
